

LifeCell launches diagnostic services

01 July 2021 | News

Immuno transplant comprehensive testing comprises end-to-end prerequisite tests for improving transplant outcome



LifeCell has ventured into a new diagnostic testing service with the launch of immuno transplant comprehensive testing. The new service comprises an array of diagnostic tests that cater to pre-and post-transplantation needs.

The comprehensive array of tests include biopsy packages, NGS-based HLA typing, infectious disease testing, and other advanced biochemical tests. The packages have been customised to suit the prerequisites for pre-and post-transplantation processes.

LifeCell has widened the state-of-the-art technology and testing expertise to the solid organ, bone marrow and cord blood transplant segment by offering key tests including the novel next-generation sequencing (NGS)-based HLA typing, flow cytometer, and Luminex-based allied tests. Notably, the success rate of a transplant is much dependent on the close match between the human leukocyte antigens (HLA) markers of the donor and the recipient in case of an organ, bone marrow, or cord blood transplant.

Ishaan Khanna, CEO, LifeCell International, said, "We have been offering the safe transplantation programme to our community cord blood banking members and this has equipped us with the relevant expertise to venture into the Immuno transplantation testing segment."